Thu, January 12, 2017

by: WOPRAI

XOMA Corporation (NASDAQ:XOMA), Down After BUYINS.NET Report Predicted Stock Would Go Down Due To Conditions Outlined In Our Re

by: WOPRAI

Endocyte Inc. (NASDAQ:ECYT), Down After BUYINS.NET Report Predicted Stock Would Go Down Due To Conditions Outlined In Our Repor

by: WOPRAI

Kite Pharma Inc. (NASDAQ:KITE), Down After BUYINS.NET Report Predicted Stock Would Go Down Due To Conditions Outlined In Our Re

by: WOPRAI

PED, NATI, ENV, GNE, SN, Expected to Trade Lower After Bearish Insider Trading

by: WOPRAI

CSM, SBNY, LLNW, SCHB, SODA, URTY Are Seasonally Ripe To Go Up In the Next Five Weeks

by: WOPRAI

HIMX, XRT, RYH, FXR, SCHX, EUFN Are Seasonally Ripe To Go Up In the Next Five Weeks

by: WOPRAI

TRNO, FNGN, WSR, AAT Are Seasonally Ripe To Go Up In the Next Five Weeks

by: WOPRAI

CLY, VR, GAZ, EXK, LOV, ISR Are Seasonally Ripe To Go Down In the Next Five Weeks

by: WOPRAI

TAC, CUTR Are Seasonally Ripe To Go Down In the Next Five Weeks

by: WOPRAI

CFNL, BBT Expected To Be Up Before Next Earnings Releases

by: WOPRAI

UNH Expected To Be Down Before Next Earnings Releases

by: WOPRAI

Brian Wieser Downgraded (ADBE) to Hold and Decreased Target to $104 on, Jan 12th, 2017

by: WOPRAI

Andrew Lim Upgraded (BAC) to Strong Buy and Increased Target to $32 on, Jan 12th, 2017

by: WOPRAI

Walter Spracklin Initiated (BA) at Sell and Held Target at $136 on, Jan 12th, 2017

by: WOPRAI

John Kim Downgraded (AIV) to Hold on, Jan 12th, 2017

by: WOPRAI

Matthew Breese Downgraded (CBU) to Strong Sell on, Jan 12th, 2017

by: WOPRAI

Mariya Kahn Initiated (AMX) at Strong Sell and Held Target at $10 on, Jan 12th, 2017

by: WOPRAI

Ken Herbert Initiated (TDG) at Buy and Held Target at $316 on, Jan 12th, 2017

by: WOPRAI

PT Luther Upgraded (CCJ) to Hold on, Jan 12th, 2017

by: WOPRAI

Curt Woodworth Downgraded (X) to Hold and Increased Target to $30 on, Jan 12th, 2017

by: WOPRAI

Meyer Shields Downgraded (THG) to Sell and Decreased Target to $81 on, Jan 12th, 2017

by: WOPRAI

Curt Woodworth Downgraded (STLD) to Hold and Increased Target to $36 on, Jan 12th, 2017

by: WOPRAI

Toshiya Hari Downgraded (SWKS) to Hold on, Jan 12th, 2017

by: WOPRAI

Darren Horowitz Upgraded (TRGP) to Buy and Held Target at $62 on, Jan 12th, 2017

Wed, January 11, 2017

by: WOPRAI

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), Down After BUYINS.NET Report Predicted Stock Would Go Down Due To Conditions Outlined

by: WOPRAI

EBR SqueezeTrigger Price is $6.62. There is $933,584 That Short Sellers Still Need To Cover.

by: WOPRAI

SYNNEX Corporation (NYSE:SNX), Up After BUYINS.NET Report Predicted Stock Would Go Up Due To Conditions Outlined In Our Report

by: WOPRAI

MV Oil Trust (NYSE:MVO), Up After BUYINS.NET Report Predicted Stock Would Go Up Due To Conditions Outlined In Our Report

by: WOPRAI

support.com Inc. (NASDAQ:SPRT), Down After BUYINS.NET Report Predicted Stock Would Go Down Due To Conditions Outlined In Our Re

by: WOPRAI

OSI Systems, Inc. (NASDAQ:OSIS), Down After BUYINS.NET Report Predicted Stock Would Go Down Due To Conditions Outlined In Our R

by: WOPRAI

AVEO Pharmaceuticals Inc. (NASDAQ:AVEO), Down After BUYINS.NET Report Predicted Stock Would Go Down Due To Conditions Outlined

by: WOPRAI

Omeros Corporation (NASDAQ:OMER), Down After BUYINS.NET Report Predicted Stock Would Go Down Due To Conditions Outlined In Our

by: WOPRAI

Prothena Corporation plc (NASDAQ:PRTA), Down After BUYINS.NET Report Predicted Stock Would Go Down Due To Conditions Outlined I

by: WOPRAI

Aduro Biotech Inc. (NASDAQ:ADRO), Down After BUYINS.NET Report Predicted Stock Would Go Down Due To Conditions Outlined In Our

by: WOPRAI

Alkermes PLC (NASDAQ:ALKS), Down After BUYINS.NET Report Predicted Stock Would Go Down Due To Conditions Outlined In Our Report

by: WOPRAI

bluebird bio Inc. (NASDAQ:BLUE), Down After BUYINS.NET Report Predicted Stock Would Go Down Due To Conditions Outlined In Our R

by: WOPRAI

VF Corporation (NYSE:VFC), Down After BUYINS.NET Report Predicted Stock Would Go Down Due To Conditions Outlined In Our Report

by: WOPRAI

Atara Biotherapeutics Inc. (NASDAQ:ATRA), Down After BUYINS.NET Report Predicted Stock Would Go Down Due To Conditions Outlined

by: WOPRAI

CIX SqueezeTrigger Price is $12.21. There is $307,400 That Short Sellers Still Need To Cover.

by: WOPRAI

ENTL SqueezeTrigger Price is $19.99. There is $13,763,472 That Short Sellers Still Need To Cover.

by: WOPRAI

Pure Cycle Corporation (NASDAQ:PCYO), Up By $0.37 (7.36%) After BUYINS.NET SqueezeTrigger Report Released on Tuesday, January 1

by: WOPRAI

Wireless Telecom Group, Inc. (NYSE:WTT), Up By $0.12 (6.98%) After BUYINS.NET SqueezeTrigger Report Released on Thursday, Janua

by: WOPRAI

ECA Marcellus Trust I (NYSE:ECT), Up After BUYINS.NET Report Predicted Stock Would Go Up Due To Conditions Outlined In Our Repo

by: WOPRAI

Park Sterling Corporation (NASDAQ:PSTB), Down After BUYINS.NET Report Predicted Stock Would Go Down Due To Conditions Outlined

by: WOPRAI

Town Sports International Holdings Inc. (NASDAQ:CLUB), Up After BUYINS.NET Report Predicted Stock Would Go Up Due To Conditions

by: WOPRAI

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), Down After BUYINS.NET Report Predicted Stock Would Go Down Due To Conditions Outl

by: WOPRAI

Akamai Technologies Inc. (NASDAQ:AKAM), Up After BUYINS.NET Report Predicted Stock Would Go Up Due To Conditions Outlined In Ou

by: WOPRAI

G Willi-Food International Ltd (NASDAQ:WILC), Up By $0.54 (8.84%) After BUYINS.NET SqueezeTrigger Report Released on Tuesday, J

Brian Wieser Downgraded (ADBE) to Hold and Decreased Target to $104 on, Jan 12th, 2017

Brian Wieser of Pivotal Research, Downgraded "Adobe Inc." (ADBE) to Hold and Decreased Target from $136 to $104 on, Jan 12th, 2017.

Brian has made no other calls on ADBE in the last 4 months.



There are 7 other peers that have a rating on ADBE. Out of the 7 peers that are also analyzing ADBE, 4 agree with Brian's Rating of Hold. Following are those relevant analyst calls for the last 4 months

  • Abhinav Kapur of "BTIG" Initiated at Hold on, Thursday, November 17th, 2016
  • Kash Rangan of "Goldman Sachs" Maintained at Hold with Increased Target to $112 on, Wednesday, September 21st, 2016
  • Keith Weiss of "Morgan Stanley" Maintained at Hold with Increased Target to $110 on, Wednesday, September 21st, 2016
  • Michael Nemeroff of "Credit Suisse" Maintained at Hold and Held Target at $105 on, Wednesday, September 21st, 2016


These are the ratings of the 3 analyists that currently disagree with Brian

  • Keith Bachman of "BMO Capital" Initiated at Buy and Held Target at $125 on, Thursday, January 5th, 2017
  • Joseph Bonner of "Argus Research" Maintained at Strong Buy on, Friday, September 23rd, 2016
  • Richard Davis of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $120 on, Wednesday, September 21st, 2016